BoD, That's an easy one, certainly less than an ounce. At least that is what it takes me to access my accounts with my trigger/mouse finger. That could go for untold larger amounts of cash for some here also; Trust, I am staying in cash for a while.
Best wishes to you, fan and all, especially those I have personally met at meetings, rum, mican, prinz, etc. You earned my respect through the sincerity of how you know followed your investment here. Special thanks to rum ;))
When the company was not sold in October, I suggested the next possible time would be when PP's options matured. Low and behold. That along with the imminent Brig approval and the bipartisan attack on drug pricing really forced the issue. Along with the lack of a Brig partner, there was no point in me analyzing much once those factors were in play simultaneously. The end was clearly imminent, no need really to post.
In the end I think the price Takeda paid was good for everyone. Since my $15 target was set, the '788 Exon20 TKI seems to have become more than viable, and I am especially impressed with the TKI approach to immunotherapy Ariad had begun. That could be an incredible game changer.
Still given the reward/risks of those developments, $24 seems about right.
To my larger goal beyond investing, Denner is not yet in the clear. Depends on if I find time to file a FOIA with the SEC. Onward. GLTA
The BoD overpaid themselves and the CEO, they breached their fiduciary responsibilities, they doctored their records and coerced and bought off their accuser...I want THE TRUTH!!!
